Method for analyzing hemoglobin and system for analyzing hemoglobin
The method and system for analyzing chromatograms in cation-exchange liquid chromatography accurately detect abnormal hemoglobin HbJ-Baltimore, addressing the issue of inaccurate HbA1c measurements by calculating peak ratios, ensuring reliable HbA1c results in the presence of HbJ-Baltimore.
Patent Information
- Application Number
- PCT/JP2024/018767
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2024-05-22
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods for measuring HbA1c using cation-exchange liquid chromatography are impaired by the presence of abnormal hemoglobins like HbJ-Baltimore, leading to inaccurate results, as they require complex confirmation procedures and cannot correctly estimate the presence of HbJ-Baltimore.
A method and system that analyze chromatograms from blood samples to detect and estimate the presence of abnormal hemoglobin HbJ-Baltimore by calculating the ratio of peak information from HbA1c and LA1c peaks, using cation exchange liquid chromatography, and identifying abnormal hemoglobin presence based on predetermined reference thresholds, preventing inaccurate HbA1c measurement reporting.
Enables accurate estimation of abnormal hemoglobin HbJ-Baltimore, thereby preventing misreporting of HbA1c results and ensuring reliable diabetes diagnosis and treatment monitoring.
Smart Images

Figure JP2024018767_28112024_PF_FP_ABST
Abstract
Description
Method for analyzing hemoglobin and system for analyzing hemoglobin
[0001] The present invention relates to a method and a system for analyzing hemoglobin. Specifically, the present invention relates to a method and a system for measuring HbA1 in a blood sample by cation exchange liquid chromatography, which can be used to estimate whether the sample contains abnormal hemoglobin.
[0002] Hemoglobin A1c (HbA1c, or stable HbA1c) is a biomarker that binds non-enzymatically to blood sugar (blood glucose) and its metabolites and is widely used in the diagnosis and treatment monitoring of diabetes. In contrast, unstable HbA1c (LA1c) is a state in which sugar temporarily binds to hemoglobin A and is not usually included in stable HbA1c.
[0003] A widely used method for measuring HbA1c is cation exchange liquid chromatography (CEX-HPLC). In the hemoglobin fraction measured by this method, peaks such as the SA1c peak, which is the HbA1c peak, as well as peaks for LA1c, hemoglobin A0 (HbA0 or A0), and fetal hemoglobin hemoglobin F (HbF or F) are separated.
[0004] The CEX-HPLC method for measuring HbA1c has the advantage of being able to detect hemoglobin fractions that arise due to mutations in the hemoglobin gene, known as abnormal hemoglobin, but has the disadvantage that the presence of these fractions may impair the accuracy of the HbA1c results.
[0005] Hemoglobin J-Baltimore (HbJ-Baltimore) is a type of abnormal hemoglobin widely found mainly in North America, and has been reported to affect HbA1c measurement results, and confirmation using electrokinetic methods, which are more cumbersome procedures, is recommended (Non-Patent Document 1). Therefore, it has been desired to estimate the presence of hemoglobin J-Baltimore in CEX-HPLC measurements as well.
[0006] Patent Document 1 discloses a method for calculating stable HbA1c taking into account the fact that when a blood sample containing hemoglobin E (HbE), a type of abnormal hemoglobin, is measured by cation exchange chromatography, a peak due to HbE appears between stable HbA1c and HbA.
[0007] JP 2012-215470 A
[0008] MA Gargollo et al., Abnormally low HbA1c secondary to hemoglobin J-Baltimore [beta 16(A13) Gly→Asp]. Family study, Endocrinol Nutr. 2010 Feb;57(2):83-5
[0009] In samples containing the abnormal hemoglobin HbJ-Baltimore, HbA1c measurement results cannot be accurately obtained. Therefore, an objective of the present invention is to develop a method or system that can estimate the presence of HbJ-Baltimore when measuring by ion exchange liquid chromatography.
[0010] As a result of intensive research into the above-mentioned problems, the inventors have found that the presence of abnormal hemoglobin (e.g., hemoglobin J-Baltimore) can be estimated from a chromatogram of a sample containing multiple hemoglobins including HbA1c and HbA0, and have completed the present invention. That is, the present invention has the following aspects.
[0011] [1] A method for analyzing hemoglobin in a blood-derived sample, comprising: (1) identifying a first peak for HbA1c and another peak (second peak) that elutes earlier than the first peak from a chromatogram showing elution of multiple hemoglobin fractions including at least HbA1c and HbA0, obtained by subjecting the blood-derived sample to cation exchange liquid chromatography; (2) calculating first peak information for the first peak and second peak information for the second peak, wherein the first peak information and the second peak information are peak heights, peak areas, or peak area ratios, respectively; and (3) estimating the presence of abnormal hemoglobin in the sample from a comparison of the ratio between the first peak information and the second peak information with a predetermined reference threshold range. [2] The method according to item 1, wherein the second peak is a peak for hemoglobin F or LA1c. [3] The method of item 1 or 2, wherein, in step (3), if the ratio of the first peak information to the second peak information deviates from the predetermined reference threshold range, it is estimated that abnormal hemoglobin is present in the sample. [4] The method of item 1 or 2, wherein, in step (3), if the ratio of the first peak information to the second peak information deviates from the predetermined reference threshold range and one or more peaks that elute slower than the first peak and are different from the peak for HbA0 are detected in the chromatogram, it is estimated that abnormal hemoglobin is present in the sample. [5] The method of item 3 or 4, wherein, if it is estimated that abnormal hemoglobin is present in the sample, one or more steps selected from the following are performed: (a) reporting the HbA1c measurement result for the sample as unreportable; and (b) reporting the HbA1c measurement result for the sample with an identifier indicating the presence of the abnormal hemoglobin. [6] The method according to any one of items 1 to 5, wherein the abnormal hemoglobin is hemoglobin J-Baltimore.[7] The method according to any one of items 1 to 6, wherein the second peak is a peak for LA1c, and in step (2), the first peak information is an area ratio of HbA1c and the second peak information is an area ratio of LA1c, and the ratio of the first peak information to the second peak information in step (3) is the ratio of the area ratio of LA1c to the area ratio of HbA1c (LA1c% / SA1c%). [8] The method according to item 7, wherein the predetermined reference threshold range is less than 0.50 or less than 0.70. [9] A hemoglobin analysis system in which the method according to any one of items 1 to 8 is performed.
[10] The hemoglobin analysis system according to item 9, comprising: a cation exchange liquid chromatography device; and an analysis means for analyzing chromatogram data acquired by the cation exchange liquid chromatography device.
[0012] According to the present invention, the presence of abnormal hemoglobin HbJ-Baltimore can be estimated, and it becomes possible to prevent reporting of inaccurate HbA1c results when HbJ-Baltimore is present.
[0013] 1 is a configuration diagram of a measurement device according to an embodiment of the present disclosure; FIG. 2 is a flowchart illustrating an example of an analysis process in the measurement device; FIG. 3 is an example of a chromatogram (measured in standard short mode) of a normal sample measured by the measurement device of FIG. 1; FIG. 4 is an example of a chromatogram (measured in standard short mode) of an HbJ sample measured by the measurement device of FIG. 1; FIG. 5 is a histogram showing the distribution of the ratio (LA1c% / SA1c%) of the area ratio of LA1c to the area ratio of SA1c in a normal sample; FIG. 6 is a histogram showing the distribution of the ratio (LA1c% / SA1c%) of the area ratio of LA1c to the area ratio of SA1c in an HbJ sample; FIG. 7 is an example of a chromatogram (measured in standard long mode) of an HbJ sample measured by the measurement device of FIG. 1;
[0014] The present invention will be described in more detail below using examples and the like, but the aspects of the present invention are not limited to these. Note that the documents cited in this specification may be incorporated into this specification in their entirety by reference.
[0015] In this specification, terms such as "first" and "second" are used to distinguish one element from another; for example, a first element may be expressed as a second element, and similarly, a second element may be expressed as a first element, without departing from the scope of the present invention.
[0016] In one embodiment, the present invention provides a method for analyzing hemoglobin in a blood-derived sample, comprising: (1) identifying a peak for HbA1c (referred to as a "first peak") and another peak (referred to as a "second peak") that elutes earlier than the first peak from a chromatogram showing the elution of multiple hemoglobin fractions including at least HbA1c and HbA0, obtained by subjecting the blood-derived sample to cation exchange liquid chromatography; (2) calculating first peak information for the first peak and second peak information for the second peak, wherein the first peak information and the second peak information are respective peak heights, peak areas, or peak area ratios; and (3) estimating the presence of abnormal hemoglobin in the sample from a comparison of the ratio between the first peak information and the second peak information with a predetermined reference threshold range.
[0017] In one embodiment, the present invention provides a hemoglobin analysis system in which the above-described method is performed. The hemoglobin analysis system provided by the present invention may include an analysis means for analyzing data on a chromatogram obtained by a cation exchange liquid chromatography device, and may be, for example, a computer having a processor (e.g., a CPU or a microcomputer) and having installed therein a control program for executing the above-described method. In another aspect, the present invention may be a computer program for causing the analysis means to execute the above-described method.
[0018] The chromatogram data obtained by the cation exchange liquid chromatography device may be introduced into the analysis means via a network (wired network or wireless network) or a storage medium (e.g., a memory device such as RAM, ROM, or flash memory, a fixed disk device such as a hard disk drive, or a portable storage device such as a flexible disk or optical disk).
[0019] In another aspect, the present invention may comprise a cation exchange liquid chromatography apparatus and an analysis means for analyzing chromatogram data acquired by the cation exchange liquid chromatography apparatus (e.g., FIG. 1). In this case, the computer serving as the analysis means may be integrally and inseparably built into the cation exchange liquid chromatography apparatus, or may be provided as an external device.
[0020] The cation exchange liquid chromatography applicable to the present invention will now be described. The cation exchange column is prepared from a packing material in which cation exchange groups have been introduced into non-porous cross-linked polymer particles. The method for synthesizing the non-porous cross-linked polymer particles is not limited, and known methods such as suspension polymerization, emulsion polymerization, seed polymerization, and precipitation polymerization can be used. Furthermore, the present invention is not limited to non-porous cross-linked polymer particles, and porous cross-linked polymers can also be used.
[0021] The monomers and crosslinking agents used in the synthesis are not particularly limited, but hydrophilic methacrylic acid and acrylic esters are preferred. Examples of monomers include hydroxyethyl methacrylate, hydroxyethyl acrylate, hydroxypropyl acrylate, glycerin methacrylate, polyethylene glycol methacrylate, and polyethylene glycol acrylate. Examples of crosslinking agents include ethylene glycol dimethacrylate, diethylene glycol dimethacrylate, triethylene glycol dimethacrylate, and glycerin dimethacrylate.
[0022] When non-porous cross-linked polymer particles are used, there are no particular limitations on the method for introducing cation exchange groups onto the surface, and any known introduction method can be used. Examples of the cation exchange groups to be introduced include sulfopropyl groups, sulfoethyl groups, and carboxymethyl groups. Similar examples can be used when porous cross-linked polymers are used.
[0023] Although there are no limitations on the HPLC method that can be applied to the present invention, it is desirable to elute one peak derived from HbJ-Baltimore earlier than the SA1c peak so as not to affect the HbA1c peak. Furthermore, since the HbF peak is used as an indicator of beta-thalassemia, it is more desirable to elute it as the LA1c peak, which is one of the peaks eluting earlier than the SA1c peak.
[0024] It is also desirable to make one peak derived from another HbJ-Baltimore to elute later than the SA1c peak and to be a peak that can be distinguished from HbA0.
[0025] Abnormal hemoglobin HbJ-Baltimore is hemoglobin having a β-globin chain mutant in which the 16th amino acid, glycine (Gly), of the β-globin chain, one of the subunits that make up hemoglobin, is mutated to aspartic acid (Asp) (see, for example, Non-Patent Document 1).
[0026] The eluent used in the cation exchange liquid chromatography applicable to the present invention is not particularly limited, and may be a buffer solution containing an organic acid such as succinic acid or citric acid and its salt, a buffer solution containing an inorganic acid such as phosphoric acid and its salt, or a mixture of organic and inorganic acids. If necessary, other salts such as sodium chloride, sodium nitrate, and sodium sulfate may be added to the buffer solution.
[0027] In the examples of this application, an automatic glycohemoglobin analyzer HLC-723GR01 (standard long mode) (manufactured by Tosoh Corporation) was used as a cation exchange liquid chromatography device to obtain a chromatogram showing the elution of hemoglobin fractions. This device is a liquid chromatography device based on the principle of cation exchange chromatography. The main system configuration of this device will be described with reference to Figure 1.
[0028] The analytical column (19) used was TSKgel GR01 (standard short mode and standard long mode) (manufactured by Tosoh Corporation), and the eluents used were GR01 eluent 1 (10), GR01 eluent 2 (11), and GR01 eluent 3 (12). Under these measurement conditions, a measurement time of 50 seconds per sample was possible.
[0029] The eluents (10, 11, 12) are delivered by a delivery pump 14 and introduced into an analytical column 19 together with a measurement sample injected by an autosampler 18. The eluents (10, 11, 12) are passed through a degasser 13 as needed, and different eluent mixture ratios are created by switching solenoid valves (15, 16, 17). The analytical column separates various components based on differences in salt concentration, etc., resulting from the mixture ratios, and the fractions are sequentially eluted. The sequentially eluted fractions are introduced into a detector 20, and the output values are continuously acquired.
[0030] The degassing device 13, solenoid valves (15, 16, 17), liquid pump 14, autosampler 18, column oven 21, and detector 20 are controlled by a control processor 22, such as a microcomputer or CPU, based on a control program and measurement conditions pre-stored in a storage unit 23. The detector signal obtained by the detector is converted by the control / processing unit 22 into plot data consisting of, for example, time and detector signal. A chromatogram is then created based on this plot data. This chromatogram is then waveform-processed, and quantitative calculation of HbA1c is performed based on pre-stored calibration data, etc. The obtained quantitative calculation results, chromatogram, etc. can be displayed on a display unit 24, and these data can also be stored in a data storage unit 25.
[0031] In one embodiment of the present invention, a chromatogram is obtained from plot data in which the horizontal axis represents time (retention time) and the vertical axis represents detector output (signal output), such as absorbance. Alternatively, the horizontal axis may represent elution volume. The vertical axis may also represent a value converted from the detector signal. For example, corrections such as noise reduction, smoothing, drift reduction, and baseline correction may be performed. Normalization may be performed to display the chromatogram and eliminate the influence of measurement conditions, environmental conditions, and other factors for comparison.
[0032] Waveform processing is performed on the chromatogram, and peak identification is performed. In samples derived from healthy individuals, six peaks are separated and identified, in order of earliest elution: HbA1a, HbA1b, unstable HbA1c (LA1c), HbA1c (SA1c), and hemoglobin A0 (HbA0). Generally, HbA1c is calculated from the ratio (proportion) of the area of the SA1c peak to the area (total area) of the entire hemoglobin. Calibration is generally performed based on the measurement results of known samples to correct for deviations in the measurement method and measurement conditions relative to the true value or reference value.
[0033] 2 is a flowchart showing one embodiment of the method of the present invention, however, the order of the steps does not necessarily follow the flowchart, and some steps may be omitted or added.
[0034] Figure 3 shows an example of a chromatogram obtained by measuring HbA1c in a typical sample (a sample from a healthy individual), and Figure 4 shows an example of a chromatogram obtained by measuring HbA1c in an HbJ-Baltimore sample.
[0035] In the flowchart of FIG. 2 , the ratio of any peak information eluting earlier than SA1c to the SA1c peak information is first calculated in the obtained chromatogram (S1). Examples of peaks eluting earlier than SA1c (corresponding to the second peak) include hemoglobin F (HbF) or LA1c, which is unstable HbA1c, and may also be peaks containing multiple hemoglobin fractions. Examples of the peak information to be compared include peak area, peak height, and peak area ratio. The peak area ratio refers to the ratio (proportion) of the area of the target peak to the area of the entire hemoglobin (total area), and may be expressed as a ratio or a percentage (%). The comparison result of the peak information calculated in S1 is then compared with a predetermined standard threshold range recorded in advance (S2). If the result deviates from the predetermined standard threshold range, it can be estimated (S3) that the sample is likely to contain abnormal hemoglobin. If the sample is presumed to contain abnormal hemoglobin and the measured HbA1c result is likely to be inaccurate, measures can be taken to make the measurement results unreportable, such as not displaying or printing the HbA1c measurement results or not transferring the HbA1c results to a higher-level host computer. Also, an identifier such as a message or flag can be added to the measurement results to indicate the possibility of the presence of abnormal hemoglobin.
[0036] On the other hand, if the comparison of S2 is within the predetermined reference threshold range, it can be determined (estimated) that abnormal hemoglobin such as HbJ-Baltimore is not present. These samples may include abnormal Hb samples in addition to standard samples, but here, abnormal hemoglobin that does not have any characteristic peak eluting earlier than SA1c is also referred to as standard sample (*).
[0037] In one embodiment of the method of the present invention, the second peak may be a peak for LA1c; in step (2), the first peak information may be an area ratio of HbA1c, and the second peak information may be an area ratio of LA1c; and in step (3), the ratio of the first peak information to the second peak information may be the ratio of the area ratio of LA1c to the area ratio of HbA1c (LA1c% / SA1c%). In this case, the predetermined reference threshold range may be set to less than 0.50 or less than 0.70. For example, if the value of LA1c% / SA1c% exceeds 0.50 or 0.70, it can be estimated that abnormal hemoglobin is present in the sample to be detected.
[0038] The present invention will be described in more detail below using examples and comparative examples, but the present invention is not limited to these examples.
[0039] In this example, measurements were performed in standard short mode with a measurement time of 30 seconds per sample, and the LA1c peak was used as the peak eluting earlier than SA1c, and the peak area ratio was used as the peak information for comparison. The area ratio of SA1c was the value after calibration.
[0040] 140 samples containing no abnormal hemoglobin were measured, and the LA1c% / SA1c% ratio for each sample was calculated. The values and frequencies were confirmed, resulting in the histogram shown in Figure 5. It was shown that for samples containing no abnormal hemoglobin, the LA1c% / SA1c% ratio was within the range of 0.10 to 0.60, regardless of the HbA1c concentration (SA1c area ratio).
[0041] Next, the LA1c% / SA1c% ratio was calculated for each of the 38 sample measurements in which HbJ-Baltimore was estimated, and the values and frequencies were confirmed, resulting in the histogram shown in Figure 6. It was shown that the ratio was within the range of 0.65 to 1.00 for all sample measurement examples.
[0042] Based on these results, 0.60 can be set as the predetermined reference threshold for the LA1c% / SA1c% ratio. Therefore, if the LA1c% / SA1c% ratio in a measured sample exceeds this value, an identifier indicating the possible presence of abnormal hemoglobin can be assigned, and the HbA1c measurement results for that sample can be made unreportable (e.g., not displayed or printed). This makes it possible to prevent the reporting of measurement results that could lead to misdiagnosis, even when measuring samples such as HbJ-Baltimore, which affects HbA1c measurement results.
[0043] Here, the identifier indicating the possibility of the presence of abnormal hemoglobin refers to a flag or message attached to the result, and may directly indicate the name of the abnormal hemoglobin or the presence of abnormal hemoglobin. Alternatively, the possibility of the presence of abnormal hemoglobin may be indirectly indicated by explaining the phenomenon, such as exceeding the LA1c% / SA1c% ratio. Furthermore, when a correspondence table or the like is provided, an identifier consisting of only a numerical value or a symbol may be assigned.
[0044] Example 2 In this example, HbJ-Baltimore was measured in standard long mode with a measurement time of 50 seconds per sample. Measurement of one sample in this example resulted in the chromatogram shown in FIG. 7 . The peak area ratio was calculated to be LA1c%: 4.46%, SA1c%: 5.48%, with an LA1c% / SA1c% ratio of 0.81. This value falls within the threshold range of 0.6 to 1.0, suggesting the possibility of HbJ-Baltimore. An unknown peak was also detected after A0. Another sample in this example was measured, and the peak area ratio was calculated to be LA1c%: 3.12%, SA1c%: 4.05%, with an LA1c% / SA1c% ratio of 0.77. This value also falls within the threshold range of 0.6 to 1.0, suggesting the possibility of HbJ-Baltimore. In addition, an unknown peak was detected after A0 in this sample as well.
[0045] Thus, it was revealed that the predetermined threshold range set in Example 1 can be commonly used even in different measurement modes. It was also revealed that the detection of one or more peaks other than the HbA0 peak that elute slower than the SA1c peak can be added as one condition for inferring the presence of HbJ-Baltimore.
[0046] REFERENCE SIGNS LIST 1 Analysis means 2 Cation exchange liquid chromatography device 10 First eluent 11 Second eluent 12 Third eluent 13 Degasser 14 Liquid feed pump 15, 16, 17 Solenoid valve 18 Autosampler 19 Analytical column 20 Detector 21 Column oven 22 Control / processing unit 23 Storage unit 24 Display unit (input unit) 25 Data storage unit
Claims
1. A method for analyzing hemoglobin in a blood-derived sample, comprising: (1) identifying a first peak for HbA1c and another peak (second peak) that elutes earlier than the first peak from a chromatogram showing the elution of multiple hemoglobin fractions including at least HbA1c and HbA0, obtained by subjecting the blood-derived sample to cation exchange liquid chromatography; (2) calculating first peak information for the first peak and second peak information for the second peak, wherein the first peak information and the second peak information are each a peak height, a peak area, or a peak area ratio; (3) estimating the presence of abnormal hemoglobin in the sample from a comparison of the ratio of the first peak information to the second peak information with a predetermined reference threshold range.
2. The method of claim 1, wherein the second peak is a peak for hemoglobin F or LA1c.
3. The method according to claim 1, wherein in step (3), if the ratio of the first peak information to the second peak information falls outside the predetermined reference threshold range, it is presumed that abnormal hemoglobin is present in the sample.
4. The method according to claim 1, wherein, in step (3), if the ratio of the first peak information to the second peak information falls outside the predetermined reference threshold range and one or more peaks that elute slower than the first peak and are different from the peak for HbA0 are detected in the chromatogram, it is presumed that abnormal hemoglobin is present in the sample.
5. The method according to claim 3, wherein, if the abnormal hemoglobin is estimated to be present in the sample, one or more steps selected from the following are carried out: (a) responding that the HbA1c measurement result for the sample is unreportable; and (b) responding with an identifier indicating the presence of the abnormal hemoglobin and reporting the HbA1c measurement result for the sample.
6. The method of claim 1, wherein the abnormal hemoglobin is hemoglobin J-Baltiomore.
7. The method according to claim 1, wherein the second peak is a peak for LA1c, in step (2), the first peak information is an area ratio of HbA1c and the second peak information is an area ratio of LA1c, and in step (3), the ratio of the first peak information to the second peak information is the ratio of the area ratio of LA1c to the area ratio of HbA1c (LA1c% / SA1c%).
8. The method of claim 7, wherein the predetermined reference threshold range is less than 0.50 or less than 0.
70.
9. A hemoglobin analysis system, in which the method of claim 1 is performed.
10. The hemoglobin analysis system according to claim 9, comprising: a cation exchange liquid chromatography device; and an analysis means for analyzing chromatogram data obtained by said cation exchange liquid chromatography device.
Citation Information
Patent Citations
Method and device for measuring glycosylated hemoglobin
JP2012215470A
Abnormal hemoglobin detection method
JP2004061461A
Quantifying method of hemoglobin f using liquid chromatography
JP2014235023A
Measuring method, measuring apparatus and eluent
JP2016027326A
Hemoglobin analyzer
JP2022090737A
